Sanofi-Synthelabo Looking Long (In Dosing), Deep (In U.S. Market) For Ambien

Sanofi-Synthelabo is considering extending the half-life of its lead product Ambien (zolpidem) in an effort to differentiate the hypnotic agent from the recently approved Wyeth-Ayerst competitor drug Sonata, Sanofi-Synthelabo Chief Operating Officer Herve Guerin indicated at Sept. 2 meeting in London.